* Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected
to show a
rise in quarterly revenue when it reports results on August 14
(estimated) for the period ending June 30 2024
* The Littleton Colorado-based company is expected to
report a
6.0% increase in revenue to $3.6 million from $3.4 million a
year ago, according to the estimate from one analyst, based on
LSEG data.
* LSEG's mean analyst estimate for Vivos Therapeutics Inc
is for
a loss of $1.05 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $7.33, above its last closing price
of $2.10.
This summary was machine generated August 12 at 11:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)